CORR Insights: A Novel System Improves Preservation of Osteochondral Allografts

C. Malemud

Abstract:T here is a relative deficiency in approved drugs for the treatment of human osteoarthritis when compared to the significant biopharmaceutical commitment for researching medical therapies for rheumatoid arthritis. Because osteoarthritis is a slowly progressive musculoskeletal disorder, clinical symptoms generally emerge after significant damage to joint articular cartilage has already occurred. However, when inflammation becomes a component of the osteoarthritis process, which often is the case, the destruction of articular cartilage becomes more prominent and highly aggressive. Additionally, repair of articular cartilage in osteoarthritis is inefficient, owing to the loss of chondrocytes by cell death. It is also likely that the vitality of the remaining resident chondrocytes become compromised as well.